Michael is responsible for expanding and improving the technology platform at Life Edit Therapeutics.
He previously held several positions at early-stage life sciences companies, including Applied Molecular Transport and Amunix, and focused on advancing delivery technologies for protein-based therapeutics.
Michael received his PhD in Chemistry from the University of California, Berkeley, where he developed new methods to study cell signaling at membrane-membrane interfaces.